BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Mysimba (naltrexone/bupropion): EMA advises about risks of using weight loss medicine Mysimba with opioids

Active substance: naltrexon, bupropion

Following a routine review of the safety of the weight loss medicine Mysimba (naltrexone/bupropion), EMA recommends strengthening existing advice to minimise the risks from interactions between Mysimba and opioid-containing medicines (including painkillers such as morphine and codeine, other opioids used during surgery, and certain medicines for cough, cold or diarrhoea).

Further information: